NEJ009 trial: a randomized phase III study of gefitinib (G) in combination with carboplatin (C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutation - Inoue, A; Hosomi, Y; Maemondo, M (J Clin Oncol, 2014)
(Suppl): abstract TPS813